Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM) Share Price

Price 211.00p on 06-01-2026 at 19:40:06
Change 9.00p 4.46%
Buy 209.00p
Sell 203.00p
Last Trade: Buy 1,649.00 at 211.00p
Day's Volume: 9,712
Last Close: 211.00p
Open: 201.00p
ISIN: KYG4672N1198
Day's Range 201.00p - 211.00p
52wk Range: 187.50p - 292.00p
Market Capitalisation: £1.81b
VWAP: 203.65184p
Shares in Issue: 859.52m

Hutchmed (HCM) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 1,649 211.00p Suspected BUY Trade
16:35:21 - 06-Jan-26
Buy* 353 208.00p Automatic Execution
16:29:29 - 06-Jan-26
Buy* 85 208.00p Automatic Execution
16:29:29 - 06-Jan-26
Sell* 25 202.00p SI Trade
16:22:01 - 06-Jan-26
Sell* 218 204.2336p Ordinary
16:03:51 - 06-Jan-26
Buy* 500 207.58p Ordinary
15:48:26 - 06-Jan-26
Buy* 10 206.65p Ordinary
15:13:53 - 06-Jan-26
Buy* 199 207.00p Automatic Execution
15:05:09 - 06-Jan-26
Buy* 71 207.00p Automatic Execution
15:05:09 - 06-Jan-26
Buy* 770 202.00p Automatic Execution
15:05:09 - 06-Jan-26
See more Hutchmed trades

Hutchmed (HCM) Share Price History

Time period:
to
Date Open High Low Close Volume
6th Jan 2026 (Tue) 201.00 211.00 201.00 211.00 9,712
5th Jan 2026 (Mon) 208.00 208.00 195.00 202.00 40,592
2nd Jan 2026 (Fri) 201.00 204.00 200.00 204.00 12,575
1st Jan 2026 (Thu) 208.00 208.00 208.00 208.00 0
31st Dec 2025 (Wed) 199.00 209.00 199.00 208.00 18,573
30th Dec 2025 (Tue) 192.00 198.50 192.00 198.50 34,925
29th Dec 2025 (Mon) 199.00 199.50 193.00 199.00 17,892
26th Dec 2025 (Fri) 196.50 196.50 196.50 196.50 0
25th Dec 2025 (Thu) 196.50 196.50 196.50 196.50 0
24th Dec 2025 (Wed) 196.50 196.50 196.50 196.50 1,030
23rd Dec 2025 (Tue) 198.00 198.00 193.00 193.00 1,777
22nd Dec 2025 (Mon) 196.50 198.00 195.00 198.00 13,824
19th Dec 2025 (Fri) 204.00 204.00 199.00 199.00 29,912
18th Dec 2025 (Thu) 200.00 204.00 200.00 204.00 24,333
17th Dec 2025 (Wed) 200.00 202.00 200.00 202.00 12,753
16th Dec 2025 (Tue) 195.50 200.00 195.50 200.00 41,894
15th Dec 2025 (Mon) 204.00 204.00 204.00 201.25 4,744
12th Dec 2025 (Fri) 198.00 204.00 197.00 204.00 26,759
11th Dec 2025 (Thu) 202.00 202.00 195.50 197.00 33,602
10th Dec 2025 (Wed) 205.00 206.00 200.00 200.00 78,382
9th Dec 2025 (Tue) 205.00 207.00 203.00 206.00 57,691
8th Dec 2025 (Mon) 210.00 210.00 209.00 209.00 8,826
See more Hutchmed price history

Hutchmed (HCM) Regulatory News

Date Source Headline
5th Jan 2026 7:00 am RNS-R Surufatinib + Camrelizumab PDAC Phase 3 initiation
31st Dec 2025 7:00 am RNS Total Voting Rights
31st Dec 2025 7:00 am RNS Total Voting Rights
30th Dec 2025 10:00 am RNS-R China NDA Acceptance-Savolitinib in Gastric Cancer
30th Dec 2025 10:00 am RNS-R China NDA Acceptance-Savolitinib in Gastric Cancer
29th Dec 2025 8:30 am RNS Blocklisting Six Monthly Return
29th Dec 2025 8:30 am RNS-R NDA Acceptance in China for Fanregratinib
29th Dec 2025 8:30 am RNS-R NDA Acceptance in China for Fanregratinib
29th Dec 2025 8:30 am RNS Blocklisting Six Monthly Return
17th Dec 2025 7:00 am RNS-R HUTCHMED Initiates Development of ATTC Candidate
See more Hutchmed regulatory news

Hutchmed (HCM) Share News

Hutchmed China kicks off phase three stage of pancreatic cancer trial

5th Jan 2026 10:45

(Alliance News) - Hutchmed China Ltd on Monday said it has started the phase three part of a trial evaluating surufatinib and camrelizumab for the treatment of pancreatic cancer in China. Read More

Hutchmed savolitinib NDA for gastric cancer accepted in China

30th Dec 2025 11:21

(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced gastric cancer, marking another regulatory step forward for the targeted therapy. Read More

Hutchmed drug gains China priority review for bile duct cancer

29th Dec 2025 10:51

(Alliance News) - Hutchmed China Ltd on Monday said Chinese regulators have accepted a new drug application for its cancer treatment fanregratinib and granted it priority review status. Read More

Hutchmed China kicks off clinical development of ATTC candidate

17th Dec 2025 13:25

(Alliance News) - Hutchmed China Ltd on Wednesday said it has begun the global phase one clinical development programme for its targeted cancer therapy for patients with solid tumours. Read More

Hutchmed drugs stay on NRDL; Tazverik added to new insurance list

8th Dec 2025 11:15

(Alliance News) - Hutchmed China Ltd on Monday said several of its oncology medicines will continue to be reimbursed under China's national insurance scheme next year, while one of its newer cancer drugs has secured a place on the country's first-ever commercial insurance drug list. Read More

See more Hutchmed news
FTSE 100 Latest
Value10,122.73
Change118.16

Login to your account

Forgot Password?

Not Registered